Latest aldafermin data in NASH weigh on NGM shares

NGM shed $2.77 (20%) to $10.78 on Monday as investors appeared underwhelmed by Phase II data for aldafermin in NASH.

Interim 24-week data from cohort 4 of an adaptive Phase II trial showed that treatment with a 1 mg daily injection of aldafermin (formerly NGM282) led to statistically significant reductions in absolute liver fat content, -7.9% vs. -2% for placebo, and a relative reduction of 39.6% vs. 5.9% for placebo (p<0.05 for both)...